Get the Weekly Intelligence Brief — top committee picks every Sunday.
SNN · NYSE · STOCK

Smith & Nephew (SNN) Stock Analysis

Healthcare Updated October 10, 2026
$27.23
52W $26.12 – $37.51
62/100
$11.44B
17.8
0.69
AI Committee Verdict
Buy
62/100
Conviction: Moderate · 60% agreement · 5 analysts
+15.3%
-12.1%
1.26:1
Moderate

Is SNN Bullish or Bearish?

Bullish. Innellis AI committee rates Smith & Nephew plc (SNN) Buy with a composite score of 62/100 , based on 5 analysts with 60% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Strong Buy
Requires a committee score of 75.0 — +13.10 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Watch
Requires the score to fall below 55.0 — -6.90 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Growth Analyst sees a compelling case — eps growing 31.7% yoy. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 3.0% pays you to wait — Value
  • EPS growing 31.7% YoY — Growth
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • Price structure making lower highs and lower lows — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
62/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 21%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ Dividend yield of 3.0% pays you to wait
Growth Analyst bullish
70 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 31.7% YoY
Technical Analyst neutral
56 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
61 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 61.9 to 61.9.

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
56.2
Neutral
MACD Histogram
0.104
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Mixed
Support
$23.93
Resistance
$31.40
Bollinger %B
0.52
Inside Bands
Price vs Moving Averages
EMA 9
$26.98 Above
EMA 21
$27.30 Below
EMA 50
$28.24 Below
EMA 200
$30.44 Below

Fundamental Analysis

Valuation
93
Growth
72
Profitability
67
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio 17.8×
P/B Ratio 2.20×
PEG Ratio 0.53
Dividend Yield 2.90%
52W High $37.51
52W Low $26.12
Quality & Growth
ROE 1181.7%
ROA 597.7%
Gross Margin 6818.1%
Operating Margin 1668.8%
Revenue Growth YoY —
Debt / Equity 0.73
AI Fundamental Assessment
P/E ratio of 17.8 (inexpensive relative to a 15-40x range); Price-to-book of 2.2x; PEG ratio of 0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 11.8%; Return on assets of 6.0%; Net margin of 10.1%; Gross margin of 68.2%; Current ratio of 2.14 (healthy short-term liquidity); Debt-to-equity of 0.73; Free cash flow per share is positive (2.00); Most recent quarter beat estimates by 0.5%; EPS growth accelerating (-4.4% -> +33.3% QoQ); Analyst estimates rising over recent quarters
Get the Full SNN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime